Theralase Reports Cancer Therapy Breakthrough
(firmenpresse) - TORONTO, ONTARIO -- (Marketwire) -- 03/28/12 -- Theralase Technologies Inc. (TSX VENTURE: TLT) announced today that its anti-cancer Photo Dynamic Compound (PDC) technology was found to completely destroy subcutaneous (under the skin) colon cancer tumours in a mouse model. Four weeks post treatment; the mice continue to be cancer free.
Dr. Arkady Mandel, Chief Scientific Officer of Theralase said, "In cancer treatment, destroying the tumour is half the battle, while the other half is preventing the cancer from recurring. These findings are important because they demonstrate that our leading drug candidate in combination with a specific dose of light can prevent the cancer from returning. Preventing cancer from recurring in animal models is an important benchmark in developing new cancer therapeutics aimed at prolonging life."
Roger Dumoulin-White, President and CEO of Theralase Inc. stated, "The achievement of this important milestone signifies that Theralase's leading drug PDC candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring. Theralase's PDC technology was able to completely destroy subcutaneous cancer in mice and allow them to live cancer free for up to 4 weeks. Mice not treated with our PDC technology did not survive even 2 weeks. Based on recent successes in our research, we are confident that Theralase is well positioned to expedite the required steps to initiate human trials in the near future."
Theralase's work in this area will be presented at an International Symposium on "Photodynamic Therapy and Photodiagnosis in Clinical Practice" conference in Brixton, Italy in October 2012.
The following summarizes the research conducted by Theralase scientists:
Theralase has a growing portfolio of intellectual property patents protecting the Theralase PDC technology for many years. Theralase's anti-cancer technology pipeline includes drug candidates, in various advanced stages of preclinical development thus preparing Theralase's anti-cancer PDC technology the ability to enter human clinical trials as early as 2013.
About Theralase Technologies Inc.:
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds (PDCs), Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses, as well as microbial pathogens associated with food contamination. For further information please visit , regulatory filings may be viewed by visiting .
This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Theralase Technologies Inc.
Roger Dumoulin-White
President & Chief Executive Officer
416-447-8455 ext. 225
Theralase Technologies Inc.
Kristina Hachey
Chief Financial Officer
416-447-8455 ext. 224
Theralase Technologies Inc.
Dr. Arkady Mandel
Chief Scientific Officer
416-447-8455 ext. 242
Theralase Technologies Inc.
Greg Bewsh
Director of Investor Relations
416-447-8455 ext. 262
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.03.2012 - 11:00 Uhr
Sprache: Deutsch
News-ID 129253
Anzahl Zeichen: 3438
contact information:
Town:
TORONTO, ONTARIO
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 197 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Theralase Reports Cancer Therapy Breakthrough"
steht unter der journalistisch-redaktionellen Verantwortung von
Theralase Technologies Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
